Avacopan Efficacy and Safety Meta-Analysis from Three RCTs

Meta-analysis data aggregates results from three randomized controlled trials (CLASSIC, CLEAR, ADVOCATE) involving 440 patients with ANCA-associated vasculitis. The dataset includes primary endpoints for clinical response, remission rates, renal function changes, and safety outcomes like adverse events. It was authored by figshare admin karger and last updated in April 2026.

Use Cases

• Compare clinical response (RR) and early remission (RR) rates between avacopan and standard-of-care regimens.
• Analyze changes in renal parameters like eGFR and renal response from aggregated trial data.
• Assess safety by examining risk ratios for glucocorticoid-related adverse events, diabetes, and psychiatric complications.
• Evaluate study heterogeneity using the I² statistic and p-values reported in the meta-analysis.

Strengths

• Aggregates data from 440 patients across three pivotal RCTs.
• Reports specific effect estimates like risk ratios (RR) and mean differences (MD) with 95% confidence intervals.

Limitations

• Limited scope with only 49.0 KB of data, indicating summary-level results rather than patient-level records.
• Derived from only three source trials, which may limit generalizability.

Provenance

Source

figshare, authored by figshare admin karger.

Collection Method

Meta-analysis of three randomized controlled trials (CLASSIC, CLEAR, ADVOCATE).

Time Range

null

Freshness

Last updated in April 2026.

Geography

null